Atlas Trials

Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma

Clinical trial NCT07047001 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT07047001
Sponsor
Dong Wen
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Renal Cell Carcinoma (RCC)Adjuvant
Start date
2025-04-24
Primary completion
2029-06-30
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.